Full transparency of ticagrelor trials in coronary artery disease should be warranted.

Autor: Ennezat PV; Cardiology department, Service de cardiologie, Centre Hospitalier Universitaire Henri Mondor, Créteil, France., Guerbaai RA; Medizinische Fakultät, Department Public Health (DPH), Universität Basel, Basel, Switzerland., LeJemtel TH; University Heart and Vascular Institute, New Orleans, LA, USA., Hansen MR; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Jazyk: angličtina
Zdroj: Hospital practice (1995) [Hosp Pract (1995)] 2022 Apr; Vol. 50 (2), pp. 89-92. Date of Electronic Publication: 2022 Mar 11.
DOI: 10.1080/21548331.2022.2049099
Databáze: MEDLINE